Neumora Therapeutics Files 8-K on Financials
Ticker: NMRA · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001885522
| Field | Detail |
|---|---|
| Company | Neumora Therapeutics, INC. (NMRA) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k, results-of-operations
Related Tickers: NMRA
TL;DR
Neumora dropped its 8-K. Check the financials.
AI Summary
Neumora Therapeutics, Inc. filed an 8-K on March 30, 2026, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and exhibits, with the primary document being an iXBRL 8-K filing.
Why It Matters
This filing provides investors with crucial updates on Neumora's financial performance and condition as of March 30, 2026.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not contain new material events or risks.
Key Numbers
- 0001193125-26-130372 — SEC Accession Number (Unique identifier for this specific filing)
Key Players & Entities
- Neumora Therapeutics, Inc. (company) — Filer of the 8-K
- 0001885522 (company) — CIK number for Neumora Therapeutics, Inc.
- 2026-03-30 (date) — Filing date and period of report
FAQ
What specific financial information is detailed in the 8-K filing?
The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing accepted by the SEC?
The filing was accepted on March 30, 2026, at 06:58:50.
What is the CIK number for Neumora Therapeutics, Inc.?
The CIK number for Neumora Therapeutics, Inc. is 0001885522.
What are the business and mailing addresses for Neumora Therapeutics, Inc.?
Both the business and mailing addresses are listed as 260 ARSENAL PLACE, SUITE 1 WATERTOWN MA 02472.
What is the SIC code for Neumora Therapeutics, Inc.?
The SIC code is 2836, categorized under 'Biological Products, (No Diagnostic Substances)'.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2026-03-30 06:58:50
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share NMRA The Nasdaq
Filing Documents
- nmra-20260330.htm (8-K) — 46KB
- nmra-ex99_1.htm (EX-99.1) — 188KB
- img49001591_0.gif (GRAPHIC) — 5KB
- 0001193125-26-130372.txt ( ) — 354KB
- nmra-20260330.xsd (EX-101.SCH) — 23KB
- nmra-20260330_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 30, 2026, Neumora Therapeutics, Inc. ("Neumora" or the "Company") announced its financial results for the fourth quarter and full year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 2.02 of this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated March 30, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUMORA THERAPEUTICS, INC. Date: March 30, 2026 By: /s/ Michael Milligan Michael Milligan Chief Financial Officer